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and a beta blocker was added to the antihypertensive therapy.
Approximately six months after surgery, the serum creatinine
was 1.0 mg/dL, and proteinuria was virtually absent (0.12
g/day). The patient did well until one month before admission;
the serum creatinine then rose slowly from 1.2 mg/dL to 2.0
mg/dL.
On admission to the hospital, her blood pressure was 110/80
mm Hg; the renal graft was neither swollen nor tender. The
CsA level was 169 ng/mL and her serum creatinine concentra-
tion was 2.1 mg/dL. Renal function, estimated by the plasma
clearance of nonradiolabeled iohexol, was 49 mL/min/1.73 m2;
renal plasma flow, measured by the renal clearance of para-
aminohippuric acid, was 208 mL/min/1.73 m2.
A percutaneous renal biopsy disclosed normal glomeruli and
arterioles. Focal isometric vacuolization of proximal tubules
was observed. Prominent tubular atrophy and striped intersti-
CASE PRESENTATION tial fibrosis were present. Mild focal collection of mononuclear
A 43-year-old woman was admitted to the Ospedali Riuniti cells in the interstitium also was documented. Intense staining
for endothelin-1 (ET-1) mRNA by in situ hybridization wasBergamo for a renal biopsy to evaluate a rising serum creatinine
found in tubules but not in glomeruli, which were essentially14 months after receiving a cadaveric renal allograft at the same
negative for the ET-1 mRNA signal. High-intensity signal forinstitution. The patient initially had developed renal failure
ET-1 mRNA was mainly observed in the epithelial cells ofdue to chronic glomerulonephritis (proliferative extracapillary
tubules located in areas of interstitial fibrosis. Staining forglomerulonephritis) and hypertension, which required chronic
MCP-1 mRNA also was selectively localized in tubules. Inhemodialysis beginning 10 years ago. After receiving a kidney
addition, the tubules stained markedly for RANTES mRNA,transplant 7 years ago, she received immunosuppressive treat-
which was also detected minimally in glomeruli.ment with cyclosporine (Sandimmune), azathioprine, and pred-
nisone.
The renal allograft functioned well initially; the serum creati-
DISCUSSIONnine concentration fell to 1.2 mg/dL on day 4 but rose to 2.1
mg/dL on day 22. The blood cyclosporine (CsA) level was 323 Dr. Ariela Benigni (Head, Department of Molecular
ng/mL. A clinical diagnosis of acute graft rejection prompted Medicine, Mario Negri Institute for Pharmacological Re-
the initiation of methylprednisolone pulse therapy. Her renal search, Bergamo, Italy): In the last 20 years, it has become
function gradually recovered; beginning on the 34th postopera-
clear that the endothelium participates directly in regu-tive day, the serum creatinine level stabilized at a baseline of
lating vascular tone through the release of a wide variety1.0 mg/dL to 1.2 mg/dL over the next 13 months. A CsA
of vasoactive substances. The discovery of prostacyclinpharmacokinetic profile performed on day 32 documented an
area-under-the-blood concentration-time curve (AUC) of 9722 in 1976 [1] was followed in 1980 by evidence that the
ng/mL/h, a blood CsA trough level of 357 ng/mL, and a peak endothelium regulates vascular smooth muscle tone by
blood CsA concentration of 1897 ng/mL (one hour after dos- elaborating potent endothelium-dependent vasodilators
ing). Along with immunosuppressants given from the immedi- [2]. Rubanyi and Vanhoutte reported in 1985 that hyp-ate post-transplant period, a calcium-channel blocker also was
oxia induces release of a diffusible vasoconstrictor sub-administered to control blood pressure. Two months after
stance from endothelial cells independent of prostaglandintransplantation, her blood pressure still was not well controlled,
synthesis [3]. But it was not until 1988 that Yanagisawa
and coworkers isolated from porcine aortic endothelial
The Nephrology Forum is funded in part by grants from Amgen, cells an extremely potent vasoconstrictor that they iden-
Incorporated; Merck & Co., Incorporated; AstraZeneca LP; Dialysis tified as endothelin-1 (ET-1) [4].
Clinic, Incorporated; and R & D Laboratories.
Synthetic pathwaysKey words: CsA nephrotoxicity, hypertension, transplant rejection,
endothelin-converting enzyme, endothelin receptors. Endothelin-1 belongs to a family of peptides compris-
ing two other isopeptides: endothelin-2 and endothelin-3.Ó 2000 by the International Society of Nephrology
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Each isopeptide contains 21 amino acids, two intrachain the peptide by endothelial and epithelial cells is predomi-
nantly toward the basolateral side [10, 11]. Angiotensindisulfide bonds constraining the overall structure, and a
conserved C-terminal sequence necessary for biologic II, TGF-b, interleukin-1, adrenalin, insulin, and physico-
chemical factors such as hypoxia stimulate ET-1 synthesis;activity [5]. Screening of a genomic DNA library allowed
cloning of three distinct human endothelin-related genes nitric oxide, natriuretic peptides, vasodilatory prostanoids,
and increased shear stress inhibit ET-1 generation [12].located in different chromosomes in human as well as
in porcine and rat genomes, each encoding a specific
Receptor familyprecursor for one of the three mature isoforms. The
59 gene-flanking region of the human ET-1 precursor Because endothelin is hydrophilic and therefore un-
able to cross the plasma membrane, it must bind tocontains consensus motifs for the binding sites of the
fos/jun complex, activating protein 1, and nuclear factor specific cell surface receptors, the expression of which
governs cell response to the peptide. Distinct endothelin1, the latter two possibly mediating angiotensin II and
transforming growth factor-b (TGF-b) induction of isoforms with diverse functions predicted the existence
of distinct receptors: indeed, two have been identifiedET-1. Sequences for the acute-phase reactant regulatory
elements probably involved in ET-1 induction under as seven transmembrane domain G protein-coupled re-
ceptors [13, 14]. Endothelin type-A receptor (ETA) hasacute physical stress in vivo are also expressed. The 39
region contains a sequence that regulates selective desta- higher affinity for ET-1 and ET-2 and lower for ET-3;
ETB, the type-B receptor, binds the three isopeptidesbilization of the ET-1 precursor mRNA, possibly ac-
counting for its short half-life [5]. These sites potentially with nearly identical affinity. The ETA receptors reside
in vascular smooth muscle cells and mediate vasocon-regulate ET-1 synthesis at the transcriptional level. The
product of the ET-1 gene transcription is preproendo- striction and cell proliferation, whereas the ETB recep-
tors on endothelial cells mediate vasodilation via nitricthelin-1, consisting of 212 amino acid residues. It is
cleaved at two sites by a neutral endopeptidase forming oxide. A variety of additional functions have been attrib-
uted to ETB receptors, however; in certain instances,the biologically inactive precursor big endothelin, which
ultimately is converted to the mature peptide by a phos- they even can elicit vessel contraction [15]. Clearance of
ET-1 from the circulation also appears linked to ETBphoramidon-sensitive membrane-bound metalloprotease
called endothelin-converting enzyme (ECE). Three dif- receptors [16]. Moreover, the ETB receptor initiates a
positive autocrine loop by which ET-1 regulates its ownferent ECE-1 isoforms differing in their N-terminal re-
gions derive from a single gene through the use of alter- gene expression by increasing preproET-1 transcription
and mRNA stability [17, 18]. Coupling of activated re-native promoters [6]. Immunofluorescence microscopy
showed distinct subcellular localizations: ECE-1a and ceptors to diverse effector systems generates second mes-
sengers. These second messengers include inositol phos-ECE-1c are localized at the cell surface, whereas ECE-1b
resides intracellularly, possibly in the trans-Golgi net- phates, diacylglycerols, and calcium and are ultimately
responsible for the biologic effects of the peptide.work [6]. Transfer experiments of ECE-1 cDNA to Chi-
nese hamster ovary cells that normally secrete only big Endothelin-producing tissues all express specific bind-
ing sites. Thus, ET is likely subject to local rather thanET-1 revealed that the extracellular form of ECE-1
cleaves the big ET-1 supplied from outside the cell, circulating hormone-type regulation. Plasma concentra-
tion of endothelins is consistently in the picomolar order,whereas the intracellular form of ECE-1 converts endog-
enously produced ET-1 [7]. This arrangement possibly far below the pharmacologic threshold. Specific binding
sites for endothelin have been identified in numerousexplains why ET-1 is generally thought to be a paracrine
and autocrine, rather than a circulating, hormone. fetal and adult organs including lung, heart, brain, and
kidney [19]. Rat cardiac atrium contains ETA receptorsTwo distinct secretory pathways for the transport and
release of ET-1 have been proposed on the basis of im- as a major component, but ETB receptors have been
reported as well. In brain, the ETB receptor appears themunoelectron microscopic localization of the peptide in
human umbilical vein endothelial cells [8] as well as in predominant subtype. The relative abundance of ETA
and ETB receptors in the kidney depends on the specieshuman coronary artery cells [9]. Endothelin-1 is continu-
ously transported in and released from secretory vesicles [19]. The ETA/ETB ratio approaches one in rats, but in
humans ETB largely prevails in renal tubules [19] andby the constitutive pathway through a cAMP-indepen-
dent mechanism. Endothelin-1 is also stored in Weiber- appears related to many physiologic functions including
sodium excretion.Palade bodies with other vasoactive compounds and is
released at the cell surface after an appropriate stimulus.
Effects of exogenous endothelinEndothelin-1 is synthesized not only in the endothelial
and smooth muscle cells of blood vessels but also in Bolus injections of nanomolar amounts of ET-1, ET-2,
and ET-3 initially lower blood pressure. This decreasethe kidney (mesangial, endothelial, and epithelial cells),
heart, brain, lung, pancreas, and spleen [5]. Secretion of results from a transient induction of prostacyclin and nitric
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oxide release from endothelial cells upon endothelial ET-1 than that from normotensive control Wistar-Kyoto
rats. Strain-related difference has been reported, how-binding of endothelin to specific receptors [20]. The dose-
dependent, remarkable increase in systemic blood pres- ever; immunoreactivity to endothelin in blood vessels
from deoxycorticosterone acetate (DOCA)-salt rats issure that follows [4, 5] is prolonged and mostly dependent
on renal, mesenteric, and muscular vessel constriction and greater than that in blood vessels from SHR rats [33].
Plasma concentrations of ET-1 in animal models of hy-is sustained by an increased cardiac output. The increase
in cardiac output is a direct effect of endothelin, as it is pertension are not raised unless accelerated hyperten-
sion is present [34]. Moreover, hepatic overexpressionnot inhibited by adrenergic receptor blockers or indo-
methacin. By contrast, the pulmonary circulation is far of human preproET-1 in rats increases plasma ET-1 lev-
els to values found in disease conditions and causes sys-less sensitive to the pressor effect of endothelins [21] and
plays a marginal role in the resultant increase in systemic temic hypertension through activation of the ETA recep-
tor [35]. Interpretation of these experimental findings isblood pressure. Endothelin of central nervous system
origin also might increase arterial pressure [22]. uncertain. Evidence for normalization of blood pressure
in genetic models by ETA or ETA/ETB receptor blockadeSystemic, but not renal, pressor effects of ET-1 were
abolished by a selective ETA receptor antagonist in rats [36, 37] suggests that ET-1 participates in the pathophysi-
ology of hypertension. But this evidence stands in con-[23]. On the other hand, both systemic and renal vaso-
constriction were prevented by a nonselective ETA and trast to findings that ET-1 knockout mice are actually
hypertensive [38].ETB receptor antagonist. This difference suggests a role
for ETB receptor in the renal response to ET-1. In hu- Data in humans also are conflicting. In support of a
role for endothelin in hypertension is the case of twomans, ET-1 infusion causes profound renal vasoconstric-
tion in healthy volunteers [24], whose systemic blood patients with malignant hemangioendothelioma, a rare
vascular neoplasm of endothelial cell proliferation, whopressure was negligibly affected [25]. Available data in
humans point strongly to a unique susceptibility of renal had systemic hypertension and elevated circulating ET-1
levels [39]. The tumors contained eight times more ET-1vessels to ET-1 vasoconstriction.
Endothelin, by its major interaction with volume regu- per gram of tissue than did normal skin. In both patients,
removal of the tumor lowered systemic blood pressurelatory hormones, takes part in volume homeostasis by
increasing plasma renin activity [26] and stimulating al- and normalized circulating ET-1. Recurrence of the tu-
mor in one of the patients was accompanied by highdosterone secretion [26]. Data that endothelin augments
atrial natriuretic peptide and inhibits peripheral nerve blood pressure and increased circulating ET-1 concentra-
tion. However, more common causes of systemic hyper-norepinephrine release highlight the complex interplay
of endothelin with volume regulatory hormones [27]. To tension are not clearly linked to high circulating levels
of ET-1. One study found high plasma ET-1 in essentialadd to the complexity, endothelin affects sodium and
water balance, so that its renal effects add to the ones hypertension [40], but other studies have not [41]. Circu-
lating plasma ET-1 levels, moreover (even when elevatedof angiotensin II (Ang II), aldosterone, vasopressin, and
atrial natriuretic peptide in regulating volume homeosta- in certain disease states), are lower than those required to
elicit most of the biologic actions of ET-1. Note, however,sis [27].
Besides its vasoactive and hormonal properties, ET-1 that like other local hormones, ET-1 acts as an autocrine/
paracrine substance on the underlying vascular smoothincreases c-fos and c-myc mRNA levels and proliferation
of cultured vascular smooth muscle cells [28, 29] and muscle, where its concentration can be several orders
of magnitude higher than that in plasma. Thus, majorstimulates mitogenesis in human umbilical vein endothe-
lial cells [30]. Further, ET-1 is a strong mitogen for mes- increases at local vascular levels might translate into
negligible increases in the periphery. For instance, inangial cells [31] and fibroblasts, and by favoring cell
proliferation, it also promotes matrix protein gene tran- atherosclerosis, vascular ET-1 increases remarkably in
the presence of only a slight increase in the peripheralscription (abstract, Ishimura et al, J Am Soc Nephrol
2:546, 1991). Endothelin-1 is chemotactic for blood mono- blood [42].
Progressive renal injury. Endothelin gene expressioncytes [32], a property which in vivo could contribute
to the tubulointerstitial damage that accompanies most and the renal synthesis of ET-1 are upregulated in animal
models of progressive renal disease that follows the lossprogressive renal diseases [32].
of a critical number of nephrons due to immune or non-
Endothelin-1 in disease immune damage to the kidney. The remnant kidney
model in rats is characterized by a time-dependent in-Hypertension. The ability of ET-1 to increase vascular
tone and to activate the sympathetic nervous system and crease in renal ET-1 gene expression, as well as an in-
crease in urinary excretion of the peptide (Fig. 1); bothrenin-angiotensin system makes it a plausible mediator
of hypertension. In-vitro mesenteric vascular tissue from correlate with progressive renal damage [43–45]. Similar
results were obtained in rats with passive Heymann ne-spontaneous hypertensive rats (SHR) generates more
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Fig. 1. (A) Time course of urinary protein excretion in rats with renal
mass reduction (RMR; d) and sham-operated controls (s). Urinary
protein excretion progressively rose with time in RMR rats (mP , 0.01
vs. day 7). At 30 (8P , 0.05) and 120 days (*P , 0.01), proteinuria was
significantly higher in RMR rats than in sham controls. (B) Renal
endothelin-1 (ET-1) mRNA expression in RMR and sham-operated
animals after surgery. (C) Corresponding densitometry of the autoradio-
graph shown in panel B. The optical density of the autoradiographic
signals was quantitated and calculated as the ratio of prepro ET-1 to
GAPDH mRNA. The transcripts of RMR kidneys were calculated rela-
tive to the mRNA levels of sham kidneys of the corresponding time.
phritis, an immune model of glomerular disease resem- man ET-2 gene are normotensive but characterized phe-
notypically by renal lesions like those seen in rats withbling human membranous nephropathy [46]. Other stud-
ies have found an upregulation of renal ET-1 and ETB a remnant kidney [51].
Several lines of evidence using ET receptor antagonistsreceptor gene expression in NZB/WF1 mice that have
an immunologic disease reminiscent of human lupus [47]. lend considerable support to the possible role of ET-1
in renal diseases and suggest important indications forGlomerular ET-1 and ETB receptor mRNAs were higher
than normal within days of puromycin aminonucleoside future clinical use of these compounds to slow or even
halt disease progression (Table 1). In the rat remnantinjection and normalized when rats were no longer ne-
phrotic [48]. Also, in experimental diabetes, mRNA for kidney model, we have shown that a specific antagonist
for the ETA receptor [52], as well as an orally active com-ET-1 is overexpressed in the kidney in the presence of
unchanged ETA and ETB receptors [49]. pound with antagonizing properties for both ETA and ETB
receptors [53], ameliorates renal functional impairmentMore direct evidence for ET-1’s role in progressive
renal damage derives from studies using transgenic ani- and protects against glomerular and tubulointerstitial
structural injury. Similar results have been obtained bymals. Mice overexpressing the human ET-1 promoter
form more ET-1 in their kidneys and develop renal le- other investigators [54]. By contrast, endothelin receptor
antagonists, which invariably reduce renal damage, didsions despite exhibiting no increase in systemic blood
pressure [50]. Furthermore, rats transgenic for the hu- not consistently normalize proteinuria. The possibility
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thus is strengthened that excessive ET-1 does not cause,
but is rather the consequence of, increased glomerular
protein traffic [32]. The renoprotective effect of ETA
receptor antagonists also was evident in mice with exper-
imental lupus nephritis [55]. The same molecule pre-
vented the development of renal lesions and attenuated
the increase in serum creatinine in rats with streptozo-
tocin-induced experimental diabetes treated at the time
of induction of the disease [56]. More recent data indicate
that an unselective ETA/ETB receptor antagonist, when
chronically administered to diabetic animals with overt
proteinuria, was as effective as was an angiotensin-con-
verting-enzyme inhibitor in reducing blood pressure and
protein excretion [57].
The renoprotective properties of endothelin receptor
blockade have been observed in other models. Develop-
ment of glomerulosclerosis and tubulointerstitial and
vascular damage in uninephrectomized stroke-prone
SHR on a high-salt diet was completely prevented by a
specific, orally active, nonpeptide ETA receptor antago-
nist [58]. More important, in these animals, the ETA
receptor blocker completely prevented death typically
resulting from salt loading. Evidence for a potential role
of ET-1 is also available in patients with chronic progres-
sive nephropathies, but data are based solely on plasma
and urine immunoreactive ET-1 measurements [59].
Plasma concentration of ET-1 in patients with end-stage
renal failure undergoing hemodialysis are one- to two-
fold greater than normal [60]. Increased circulating ET-1
concentration might reflect impairment of clearance.
However, the fact that urinary excretion of ET-1 is also
increased in patients with chronic glomerulonephritis
[59] suggests that renal generation of ET-1 in these dis-
eases is increased. Moreover, administration of an ETA/
ETB receptor antagonist to patients with chronic renal
failure reduced blood pressure and renal vascular resis-
tance [61].
Cyclosporine-induced renal hypoperfusion. In vitro
evidence indicates that cyclosporine A (CsA) increases
the release of ET-1 from glomerular endothelial, mesan-
gial, and epithelial cells [62–64]. In another study, rat
mesangial cells exposed to CsA expressed more mRNA
for preproET-1 and ETB receptor than cells exposed
to vehicle, while the expression of ETA receptor was
unchanged [65]. Moreover, CsA induces renal endo-
thelin receptor upregulation [66–68]. In vascular endo-
thelial cells, CsA upregulates the ET-1 gene by acting
on its promoter through calcineurin-dependent dere-
pression of the ET-1 gene (Marsen et al, 35th Congr Eur
Renal Assoc, Rimini, Italy, 1998). Cyclosporine-induced
renal vasoconstriction is mediated by ET-1 in afferent
arterioles, as documented by experiments performed in
an in vitro vascular experimental system [69]. In 1991,
studies using isolated perfused rat kidney found that CsA
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increased renal vascular resistance and reduced renal
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perfusate flow [70]. Such changes were effectively pre-
vented if isolated kidney preparations were pre-exposed
to a specific anti-ET-1 antibody [70]. A similar protective
effect was observed after in vivo infusion of a specific
anti-ET-1 antibody in animals in which renal plasma
flow (RPF) and glomerular filtration rate (GFR) were
reduced by CsA [70]. Micropuncture studies have subse-
quently confirmed a role for ET-1 in CsA-induced vaso-
constriction by showing that an anti-ET-1 antibody was
protective [71]. Both ETA or mixed ETA/ETB receptor
antagonists [72, 73] were capable of ameliorating or even
preventing acute CsA-induced renal vasoconstriction.
Studies have found that in vivo administration of CsA
increases renal synthesis of ET-1 by regulating mRNA
transcription of the peptide. After CsA injection, an
early increase of preproET-1 glomerular mRNA was
reported in the presence of ECE-1, ETA and ETB mRNA,
and ECE-1 protein level downregulation [76].
In human renal transplantation, we found that each
administration of CsA was invariably associated with a
reduction in RPF and GFR. These changes were tran-
sient and negatively correlated with the maximum CsA
blood concentration [75]. In these patients, RPF and
GFR declined two to four hours after the maximum CsA
concentration was reached. This event was associated
with an increase in urinary excretion of ET-1, which
occurred six hours after CsA dosing and returned to the
Fig. 2. (A) Monitoring of renal plasma flow in renal transplant patientsnormal range in the subsequent six hours (Fig. 2) [75].
given 5 mg/kg cyclosporine A (CsA). (B) Urinary excretion of ET-1 in
We thus speculated that the transient increase in the renal transplant patients whose renal function is reported in panel A.
Urines were collected before (basal) and after (0–6 h and 6–12 h)renal synthesis of ET-1 mediates the daily acute renal
administration of 5 mg/kg CsA. *P , 0.01 vs. basal and 6–12 h.hypoperfusion observed in renal transplant patients
given CsA to prevent graft rejection.
Chronic CsA nephrotoxicity. Rats given CsA for 30
days have abnormally high urinary big ET-1 and ET-1
values. The latter was positively correlated with the de- evaluated by in situ hybridization in tubular epithelial
velopment of renal insufficiency [76]. Therefore, studies cells, particularly in those tubules located in areas of
were designed to address whether CsA nephrotoxicity interstitial fibrosis. We suggested that the exaggerated
is also mediated by exuberant formation of ET-1. Salt- synthesis of ET-1 by these patients’ tubular epithelial
depleted rats given CsA daily for five weeks indeed had cells renders them a source of inflammation, which in
a progressively deteriorating GFR and developed tubu- turn causes interstitial inflammation and triggers the de-
lointerstitial fibrosis [73]. An ETA/ETB receptor antago- velopment of renal interstitial fibrosis [78].
nist strikingly perserved renal function but did not pro- Transplant rejection. Changes in ET-1 gene expres-
tect from structural damage induced by CsA [73]. sion and enhanced synthesis of the corresponding pep-
Renal transplant patients undergoing long-term CsA tide have been reported in experimental renal trans-
treatment exhibit increased renal synthesis of ET-1, as plantation, but such changes were not confined to kidney
documented by increased urinary excretion of ET-1 transplant models. Vascularized rat cardiac allografts,
[75, 77]. We also recently found an intense staining for while undergoing rejection, display a significant upregu-
ET-1, RANTES, and MCP-1 mRNAs selectively local- lation of ET-1 mRNA and peptide expression, mainly
localized in mononuclear cells infiltrating the interstitiumized at tubular epithelial cells in biopsy specimens from
patients with light microscopic evidence of chronic CsA of the graft [79]. Elevation of plasma ET-1 also was
reported in cases of vascular rejection [80], but findingsnephrotoxicity but not in patients which chronic graft
rejection (Fig. 3) [78]. The patient presented in this Fo- were not consistent [77]. In forms of hyperacute vascular
rejection, as in discordant xenotransplantation, measure-rum belonged to the group of patients with CsA nephro-
toxicity and showed high expression of ET-1 mRNA ments of renal vein ET-1 disclosed very high levels [81].
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Fig. 3. (A) Representative pictures of ET-1 in situ hybridization in the
kidney from a patient with CsA toxicity (left) and from a patient with
chronic graft rejection (right). Intense staining was found in tubuli
(magnification 3360) from patients with CsA toxicity. (B) Frequency
of positive tubular staining for ET-1 in the kidney allograft biopsies
from patients with CsA toxicity, chronic graft rejection, and no lesions
at light microscopic evaluation. Positivity was considered when score
staining intensity was $1 in two or more tubuli. The ratio on top of
each column represents positive staining/total biopsies analyzed.
Chronic rejection of the rat cardiac allograft also is Conclusions
associated with increased ET-1 levels in ventricular tis- Although renal vessels are very sensitive to the con-
sue, and with strikingly augmented immunoreactivity of strictor effect of exogenous endothelin, it is still far from
intimal myocytes at sites of intimal proliferation; this clear whether endogenously produced endothelin helps
increase occasionally occurred in cardiac myofibers im- maintain renal function in normals. Intensive research
mediately adjacent to areas of interstitial inflammation carried out in the last few years, however, has shed light
or fibrosis [82]. In a model of chronic renal allograft on a possible role for endothelin in the mediation of
nephropathy, pharmacologic manipulation of the endo- hypertension and acute and chronic renal dysfunction.
thelin system in the rat by a selective ETA receptor antag- Several clinical studies have indicated that in patients
onist ameliorated renal dysfunction, prevented renal with systemic hypertension, progressive proteinuric ne-
damage [83], and even prolonged survival (abstract, phropathies, or acute and chronic renal dysfunction due
Rohmeiss et al, J Am Soc Nephrol 9:656A, 1998). Thus, to CsA therapy, the endothelin pathway is activated, as
elevated amounts of ET-1 likely play an adverse role in previously observed in experimental animals. Convinc-
the organ dysfunction associated with chronic rejection ing pre-clinical observations suggest strongly that endo-
processes. thelin antagonists are likely to have a promising role in
An early increase in plasma ET-1 levels in patients the future treatment of cardiovascular diseases and acute
with solid organ transplants including kidney, heart, renal dysfunction (mainly the form associated with CsA
heart-lung, and liver has been consistently documented toxicity), and in preventing progressive deteriorating re-
[84]. Vascular damage and fibrogenesis in transplant re- nal function in proteinuric nephropathies. Patients with
cipients with chronic allograft rejection is substantially essential hypertension might benefit from the ET recep-
prevented by losartan, which significantly lowered plasma tor antagonists, but the advantages, if any, of this drug
class over conventional antihypertensive therapy are un-levels of ET-1 and TGF-b [85].
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known. We can also consider the possibility that endo- effect of Ang II is mediated by ET-1, as suggested by
studies with monoclonal antibodies against ET-1 [87] orthelin antagonists, by suppressing one of the factors with
inflammatory and fibrotic potential, are renoprotective drugs that block the ET receptors [88]. Futhermore, a re-
ciprocal regulation of Ang II and ET-1 on matrix proteineven independently of favorable changes in renal hemo-
dynamics. We can anticipate that recent developments synthesis and cell proliferation via ETA and AT1 receptors
has been suggested in rat mesangial cells [89]. Whetherin cell biology and pharmacology of endothelins will
translate in the next few years into novel treatments for ET-1 also contributes to the ability of Ang II to impair
glomerular permeability to macromolecules in animal andthe cardiovascular and renal diseases for which solid
evidence of excessive local formation of the hormone human proteinuric nephropathies is controversial, how-
ever. Data indicate that in animals with progressive ne-has been documented.
phropathies, ACE inhibitors, besides reducing glomeru-
lar protein traffic, also inhibit the exaggerated synthesis
QUESTIONS AND ANSWERS
of ET-1 [46]. On the other hand, findings that protein
Dr. Nicolaos E. Madias (Chief, Division of Nephrol- overload increases ET-1 generation in proximal tubular
ogy, New England Medical Center, Boston, Massachusetts, cells in vitro [11] can be taken to indicate that the ET
USA): Thank you, Dr. Benigni, for this wonderful presen- synthetic pathway in proximal tubular cells can be
tation. Is the upregulation of ET-1 in the various renal influenced, at least in part, by the process of protein
diseases you discussed largely driven by angiotensin II? reabsorption.
Dr. Benigni: A number of studies have suggested that Dr. Madias: What is known about the clearance and
in proteinuric progressive nephropathies, excess protein degradation of ET-1? What are the implications for these
reabsorption stimulates proximal tubular epithelial cells functions of ET receptor antagonism?
to form excessive amounts of ET-1. In rats with progres- Dr. Benigni: Although several ET-degrading enzymes
sive renal disease, ACE inhibitors reduced the protein have been described in the kidney, endothelin degrada-
excretion rate as well as the exaggerated tubular synthe- tion mainly is due to neutral endopeptidase EC 3.4.24.11,
sis of ET-1 [46]. ACE inhibitors and Ang II receptor a membrane-bound enzyme widely involved in the deg-
blockers are the only drugs that consistently reduce pro- radation of peptide hormones [90]. As for ET-1 clearance
teinuria in animals and humans. Thus, we cannot con- from the circulation, ETB receptors could act as clearance
clude from these experiments whether changes in ET-1 receptors [16]. The fact that this receptor subtype is
production were a direct effect of protein overload or upregulated in the kidney in many pathologic conditions
depended on Ang II, a well-known stimulator of ET-1 associated with increased ET-1 synthesis suggests that
synthesis in renal cells. However, preliminary data (Zoja ETB contributes to regulating the local formation of
C, unpublished obervation) indicate that in rat models, ET-1. The correct answer to your question will derive
whenever a dose of an ACE inhibitor high enough to from studies with ETB receptor antagonists that only
completely inhibit ACE activity failed to reduce protein- recently are available for chronic studies.
uria in cases of advanced or particularly severe disease, Dr. Helmy M. Siragy (Professor of Medicine, Univer-
it did not halt disease progression and also did not affect sity of Virginia, Charlottesville, Virginia, USA): You con-
the increased urinary ET-1 excretion. I know of similar centrated your discussion on ET-1. Do you know what
preliminary data in humans. In patients with type-II dia- happens to the other endothelins, ET-2 and ET-3, in
betes in an advanced phase of the disease—so advanced CsA-induced nephrotoxicity?
that ACE inhibitors failed to reduce proteinuria—the Dr. Benigni: Recent gene-targeting studies have re-
disease progressed despite complete ACE inhibition. vealed unexpected roles for endothelin isoforms in the
Dr. Madias: Dr. Remuzzi, do you wish to add some- development of neural-crest-derived tissues. Further-
thing on this issue? more, mice deficient in either ET-3 or ETB receptors
Dr. Giuseppe Remuzzi (Director, Negri Bergamo Lab- develop spotted colors and aganglionic megacolon [91].
oratories; Chief, Division of Nephrology, Azienda Ospeda- Scanty evidence is available for the function and localiza-
liere, Ospedali Riuniti; Bergamo, Italy): The possibility tion of ET-2 and ET-3 isoforms in the normal kidney.
that Ang II is a direct stimulus for upregulating the Specific RNase protection assays revealed expression of
intrarenal synthesis of ET-1 in progressive renal disease the three genes encoding ET-1, -2, and -3 in the rat
cannot be completely excluded. Angiotensin II stimu- kidney [92]. Human kidney contains mRNA encoding
lates the expression of the ET-1 gene in endothelial and all three peptide isoforms, as documented by RT-PCR,
renal cells. Infusion of Ang II increases functional ECE but only mature ET-1 and big ET-1 peptides could be
activity in vascular smooth muscle and kidney via the detected by immunocytochemistry [93]. As for the effect
ETA receptor, the expression of which is upregulated by of ET-2 and ET-3 on renal function, infusion of both
Ang II in vascular smooth muscle cells, cardiomyocytes, peptides in the porcine kidney caused vasoconstriction
and significant increases in splenic and femoral vascularand mesangial cells [86]. Moreover, part of the mitogenic
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resistance. No data are available on the role of ET-2 and to an increased concentration of protein, they produce
much more TGF-b than in resting conditions (abstract,ET-3 in renal diseases.
Dr. David P. Brooks (Director of Renal Pharmacol- Uchida et al, J Am Soc Nephrol 9:529, 1998), so it is
possible that, besides a direct effect of protein overloadogy, SmithKline Beecham Pharmaceuticals, King of Prus-
sia, Pennsylvania, USA): The data demonstrating the on ET-1, proteinuria also stimulates TGF-b, which in
turn stimulates ET-1. We tried extensively in the pasttubular expression of ET-1 in CsA nephrotoxicity but
not in allograft rejection are quite convincing. You also to study in vivo the relationship between TGF-b and
ET-1 in proteinuric renal disease, but the problem withdemonstrated in the rat an increase in urinary excretion
in ET-1 with CsA treatment [76]. My questions are: did TGF-b is the lack of inhibitors, apart from decorin, that
are efficient enough to bind the cytokine. With the avail-today’s patient have an increased urinary excretion of
ET-1? If so, could that be a better diagnostic test than ability of soluble receptors for TGF-b, this issue possibly
could be addressed.renal biopsy? What is the diagnostic value of renal biopsy
in assessing ET-1 expression? Dr. Madias: Are there polymorphisms in the genes
of the ET-1 system and its receptors in essential hyper-Dr. Benigni: We did not measure urinary excretion of
ET-1 in the patients discussed today. We only measured tension and renal failure?
Dr. Benigni: Evidence indicates molecular variationsurinary excretion of ET-1 and big ET-1 in the urine of
rats after chronic administration of CsA and found both in the coding regions and upstream of the ETA and ETB
genes [99–101], but association of the detected polymor-levels increased [76]. It should be very interesting to
address the diagnostic value of renal biopsy in assessing phisms with blood pressure levels and myocardial in-
farction was negative [99]. Instead, a polymorphism ofrenal ET-1 expression in patients with CsA nephrotox-
icity. the ETA gene might influence the pulse pressure [102].
Moreover, polymorphisms of the ET-1 gene might modifyDr. Gian Paolo Rossi (Dipartimento di Medicina Clin-
ica e Sperimentale, University of Padova, Padova, Italy): the phenotypic expression of left-ventricular hypertrophy
in patients with hypertrophic cardiomyopathy [100]. NoI would like to comment on the possible stimulatory
effect of Ang II on ET-1 mRNA expression in the kidney. association was found in ET-1 gene polymorphism and
cardiac allograft rejection or vasculopathy [101].In my view, what is most striking is that ET-1 mRNA
expression is localized in the tubuli and not in the glomer- Dr. Madias: Let me change the topic a bit. Could you
comment on the rationale and the concerns of employinguli, where one would have expected most Ang II to be
synthesized. selective versus nonselective ET receptor antagonists in
treating cardiovascular and renal disorders?Dr. Remuzzi: Actually data indicate that Ang II is
synthesized in the proximal tubule [94], thus leaving open Dr. Benigni: We have reported a renoprotective effect
of ETA and ETA/ETB receptor antagonists in differentthe issue of the relation between Ang II and ET-1 synthe-
sis. Indeed, recent findings support an autocrine/para- experimental models of renal diseases [52, 53, 57], but
we did not formally compare both types of compoundscrine role for Ang II within the proximal tubule [95].
All the components of the renin-angiotensin system exist in the same setting. Nabokov and coworkers did the
comparison in the renal mass reduction model, in whichwithin the proximal tubule. Angiotensinogen and its
mRNA are present in the proximal tubule, and renin both selective and unselective ET antagonists equally
interfered with the development of glomerulosclerosisactivity along with renin mRNA are present in lysates of
proximal tubule cells in primary culture [96]. Moreover, independently from an effect on systemic blood pressure
[54]. However, given the role of the ETB receptor onACE activity has been localized on the luminal brush-
border membrane [97]. water and sodium handling, and the capacity of such a
receptor subtype to act as a clearance receptor, it wouldDr. Siragy: I agree that the levels of Ang II are much
higher in the tubuli. Actually, we found a 1000-fold seem reasonable to spare the ETB receptor. Differences
between species in function and distribution of ET recep-higher Ang II level in the renal interstitium with respect
to circulating blood [98]. The issue is also complicated tors also should be taken into account.
Dr. Brooks: We’ve also demonstrated a species differ-by TBF-b1. We know that proteinuria can stimulate
TGF-b1; we know that Ang II can stimulate TGF-b1; ence between the ETA and ETB receptor function in the
rat and the dog [103]. What are the data in humansand we know that this factor is also present in the tubuli.
So my questions are: do you think that the proteinuria suggesting that the ETA receptor is primarily involved
in vasoconstriction and that the ETB receptor affectsdirectly stimulates ET-1, or is it mediated by TGF-b1?
Is there any relationship between the level of proteinuria, sodium excretion?
Dr. Benigni: In humans, the involvement of the ETAmacroalbuminuria versus microalbuminuria, and ET-1
production? and ETB receptor subtypes in vasoconstriction and so-
dium retention have been documented by Dr. Rabelink’sDr. Benigni: There is very preliminary experimental
evidence that when proximal tubular cells are exposed group through the infusion of ET-1, an unselective ETA
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and ETB receptor agonist, and ET-3, a selective ETB of question. Based on available experimental and clinical
data, I would select chronic nephropathies, either dia-agonist [104]. Equimolar amounts of ET-1 and ET-3
capable of inducing similar increases in plasma levels of betic or nondiabetic, in an attempt to identify patients
for whom ACE inhibitors are not adequate. Some pa-ET isoforms were used in these experiments. Infusion
of ET-1 induced an increase in mean arterial pressure tients only partially respond to ACE inhibitors; others
do not respond at all. A multidrug approach, whichof 6 mm Hg accompanied by strong renal vasoconstric-
tion and sodium retention. Infusion of ET-3 had neither would add ET receptor antagonists to the best-available
treatment in these patient groups would probably be ofsystemic nor renal effects. These findings suggest that
the renal vasoconstrictor effect in humans is mainly me- most value. Enough experience has been accumulated
to suggest that ETA receptor blockers probably are thediated by the ETA receptor.
Dr. Madias: What is the basis of the excessive sensitiv- best class of compounds to start with.
Dr. Madias: What is known about the mechanism ofity of the kidney to the vasoconstrictive properties of ET-1?
Dr. Benigni: The peculiar sensitivity of renal vessels autoinduction of ET-1?
Dr. Benigni: ET-1 autoinduction has been describedto ET-1 vasoconstriction has been demonstrated in dif-
ferent species including the pig, rat, and human, but as in neonatal cardiomyocytes, human umbilical vein endo-
thelial cells, and mesangial cells. In this last cell type,far as I know, nobody has explained why the renal vessels
are so sensitive to ET-1. It is possible that a particular ET-1 stimulates its own synthesis and production by in-
creasing the transcription and stability of preproET-1hemodynamic condition in the kidney accounts for this
feature. mRNA. ET-1 autoinduction is mediated through the
ETB receptor in mesangial cells and human umbilical veinDr. Mauro Abbate (Mario Negri Institute for Pharma-
cological Research, Bergamo, Italy): You mentioned that endothelial cells [17, 18]; in cardiomyocytes, this receptor
subtype is only partially involved. The demonstration ofCsA can stimulate the synthesis of ET-1 in several cell
types. Do you know whether it does so in proximal tubu- autoinduction, already described for other growth fac-
tors including TGF-a, B-chain of PDGF, and TGF-b, ledlar epithelial cells and by which possible mechanism?
Dr. Benigni: Data show that CsA indeed increases to the hypothesis that autoinduction could be responsible
for the potent and long-lasting effect of ET-1 [4].ET-1 mRNA and synthesis in different glomerular cells,
including endothelial and mesangial cells [62, 63]. Also, Dr. Madias: Does the relative abundance of ET recep-
tors change under pathologic conditions?data from Japan show that ET-1 synthesis is increased
in a tubular cell line after exposure to CsA [64]. As for Dr. Benigni: Studies have consistently indicated a se-
lective upregulation of ETB receptor in disease condi-the molecular mechanism by which CsA can induce ET-1
release, very little is known so far. Recent evidence in tions, while expression of ETA remains unaltered. This
phenomenon has been described in experimental CsAcultured endothelial cells showed that CsA can induce
ET-1 gene expression by acting on the ET-1 promoter nephrotoxicity, in the renal mass reduction model, in
mesangial proliferative nephritis, in puromycin amino-through a calcineurin-dependent mechanism (Marsen et
al, 35th Congr Eur Renal Assoc, Rimini, Italy, 1998). nucleoside glomerulonephritis [53, 66, 106, 107] and re-
cently in patients with glomerulonephritis and high levelsDr. Albert Ong (University Section of Medicine, Clin-
ical Sciences, Sheffield, United Kingdom): In 1995 we of proteinuria (abstract, Lehrke et al, J Am Soc Nephrol
10:80A, 1999).showed that CsA can increase ET-1 production in freshly
isolated human proximal tubular cells, but the effect was Dr. Madias: What about the endothelin-converting
enzyme (ECE) as a target of therapy? What do we knowsmall in vitro [105]. May I make two other comments?
First, in my experience with cultured cell ET-1 produc- in terms of specific nephropathies, and what direction
should we take?tion, there are factors that specifically regulate ET-1 pro-
duction in different cell types, including the human tubu- Dr. Benigni: At present there are only data with phos-
phoramidon, which has the disadvantage of inhibitinglar epithelium. Second, as for the question of which
receptor you should block, in cultured tubular epithe- both ECE and neutral endopeptidases. As for the selec-
tive ECE-1 inhibitors, Dr. Loeffler has accumulated somelium, the ETB receptor appears to be responsible for
mediating mitogenesis, and it also appears to mediate nice data, but his work was mainly in vitro (unpublished
data). I personally feel that this is a direction to pursue,the phenomenon of autoinduction of ET-1, so it might
be beneficial to block this receptor as well. Here is my because I would expect that ET antagonists would not
afford 100% inhibition of ET binding to the receptors.question: if you were from a drug company willing to
fund research in nephrology, what group of patients Theoretically, a drug that can bind to ET receptors and
at the same time inhibit ECE-1 synthesis would be thewould you study, and what drug would you use?
Dr. Benigni: I think that the best person to answer ideal compound to use.
Dr. Bernd-Michael Loeffler (Hoffmann-LaRoche,your question is a clinician.
Dr. Remuzzi: It is always difficult to answer this kind Basel, Switzerland): Due to the fact that urinary ET-1,
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to the best of my knowledge, is not coming from the tor antagonists in women of childbearing age. As for the
adverse events in clinical trials, the most common iscirculation but from the kidney, my question is: do we
have any knowledge about whether urinary ET-1 corre- headache. It is unclear whether headache occurs to a
greater or lesser degree with ETA or ETB receptor antag-lates with disease progression and whether we can use
it as a marker of severity of a given disease? onists. The headaches also tend to go away with contin-
ued use of the drug. But we should be able to identifyWith respect to ECE as a target therapy for patients
with renal disease, this is a very interesting but also very efficacious doses and eliminate headache as a side effect.
Dr. Norbert Bender (Knoll AG, Ludwigshafen, Ger-complicated issue, because the kidney expresses high
levels of ECE but also of neutral endopeptidase (NEP). many): We also observed headache as the most promi-
nent side effect of our ETA receptor antagonist; it is theThe issue is complex because NEP is unspecific due to
its actions on atrial natriuretic peptide, brain natriuretic nitrate type of headache with pulsing pain and red face.
Do your patients experience a similar type of headache,peptide, and sodium homeostasis and because it trans-
forms big ET-1 into ET-1 and then ET-1 into inactive or was theirs akin to a migraine? We also had the impres-
sion that healthy volunteers and patients with hyperten-fragments. What about the proper balance of ECE/NEP
in the kidney? This is at present completely unknown, sion are more sensitive to headache than are patients
with congestive heart failure.as no studies are available with specific compounds. The
theoretical possibility exists that inhibiting ECE in the Dr. Brooks: That is interesting. The type of headache
we observed with the mixed antagonist is, in fact, thekidney will serve to accumulate big ET-1, which can be
cleaved by NEP and then return to the system. nitrate-type, pulsing headache, but we only observed those
headaches when we used high concentrations. I agreeDr. Benigni: The significance of ET-1 urinary excre-
tion has been addressed by previous studies. Using a rat with you on the second issue; we also had the impression
that normal, healthy young volunteers had more fre-model, we infused radiolabeled ET-1 into the blood and
measured its radioactivity in the urine. The ET-1 level quent headaches than did the patients.
Dr. Rossi: One of the reasons why normal volunteerswas very low and accounted only for 0.2% or 0.3% of
total radioactivity injected [43]. By performing HPLC have more frequent headaches than do patients with
chronic heart failure could be that the latter group hasanalysis of the radioactive material in the urine, we found
that the chemical nature of the labeled ET-1 recovered dysfunctional endothelium, which might not make enough
nitric oxide to produce pain.in the urine was different from that of the native peptides.
This observation suggested that ET-1 excreted in the Dr. Loeffler: I think you are right. It is not just a
dose effect, because in the investigations with bosentanurine reflects its renal synthesis rather than changes in
the systemic circulation [43]. These findings have been (an ETA/ETB antagonist) in patients with chronic heart
failure, the dosing was quite high. Yet they had manyconfirmed in anesthetized dogs [90]. Moreover, injection
of neutral endopeptidase inhibitors into anesthetized fewer headaches than did normal subjects infused with
comparable doses.rats concomitant with radiolabeled ET-1 infusion mark-
edly increased ET-1 urinary excretion [90]. The study Dr. Marina Noris (Head, Laboratory of Transplant
Immunology, Mario Negri Institute for Pharmacologicalindicated that the neutral endopeptidase plays a major
role in ET-1 degradation in the kidney. As far as the Research): In experimental models of renal disease, the
regulation of ET-1 and nitric oxide is reciprocal in thatpredictive value of urinary ET-1 excretion in patients,
data show increased urinary excretion of ET-1 in patients upregulation of ET-1 is associated with downregulation
of nitric oxide [108]. What do you think about the possi-with progressive renal disease, including membranopro-
liferative glomerulonephritis, lupus nephritis, and IgA ble impact of selective or unselective ET receptor antag-
onists on renal nitric oxide in renal disease?nephropathy [59], in subjects with unilateral nephrec-
tomy and in diabetic patients with microalbuminuria. Dr. Benigni: Some of the studies on reciprocal regula-
tion of ET-1 and nitric oxide that you refer to are mainlyBut I know of no serial measurements of urinary ET-1
in patients with renal disease. in vitro studies. We studied this issue in vivo using a
selective antagonist of the ETA receptor in rats with renalDr. Madias: Given the major phenotypic abnormali-
ties of animals rendered deficient of ET-1 or its receptors, mass reduction that had a reduced renal synthesis of
nitric oxide. In these animals, after one month of treat-what is known about the toxicity of the antagonists?
What are the most important adverse effects encoun- ment, the beneficial effect of an ETA receptor antagonist
was associated with an increased renal nitric oxide syn-tered in clinical trials?
Dr. Benigni: Dr. Brooks, would you speak about your thesis over that in untreated rats [109]. The opposite is
also true. After one year of administration of the nitricexperience with ET receptor antagonists in human radio-
contrast nephropathy? oxide donor molsidomine to animals with renal mass
reduction, a significant renoprotective effect, possiblyDr. Brooks: Given the defects associated with the
ET-1 knockout mice, I would suggest not using ET recep- mediated by a reduction in the exaggerated ET-1 urinary
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excretion, occurred [110]. Another study in the same [75]. I am not aware of other studies with Sandiummune
or Neoral, but certainly they should be very interesting.animal model has suggested that the beneficial effect of
l-arginine administration was attributable to a decrease Dr. Siragy: Does CsA increase expression of ET re-
ceptors or their sensitivity?in glomerular ET-1 [108].
Dr. Piero Ruggenenti (Chief, Department of Renal Dr. Benigni: Pioneer studies by Drs. Kon and Brooks
in rats acutely treated with CsA showed an increase inMedicine, Clinical Research Center for Rare Diseases,
Ranica, Bergamo): You provided the evidence that in ET receptor density in rat glomerular and medullary
membranes [68, 71]. In 1990, when these studies weremodels of renal disease progression, increased urinary
protein excretion was associated with increased renal published, ETA and ETB receptors had not yet been
cloned, and the authors could not describe CsA’s effectproduction of ET-1 and increased ET-1 excretion. On
the other hand, you also said that in proteinuric chronic on different receptor subtypes. With the discovery of
ETA and ETB receptors, Dr. Kon’s group showed a selec-nephropathies, ACE inhibitors decrease proteinuria, are
renoprotective, and limit ET-1 production and its excre- tive upregulation of prepro ET-1 and ETB but not ETA
receptor gene expression in the rat medulla after acutetion in the urine. So my question is: to what extent and by
what mechanism do you think ET receptor antagonists or CsA administration [66].
Dr. Brooks: Dr. Kon’s team showed very nicely thatinhibitors of ECE could offer additional renoprotection
to animals or even humans with chronic nephropathies CsA treatment in rats causes profound and progressive
deterioration of renal function associated with structuralwho are already taking ACE inhibition therapy?
Dr. Benigni: I would predict that in patients who do injury. In a later study, ET receptor antagonism strik-
ingly preserved renal function but did not protect ani-not respond completely to ACE inhibitors, adding an
ET receptor antagonist or an ECE inhibitor could confer mals from the development of structural damage that,
by contrast, was reduced by administration of an ACEadditional renoprotection as compared to using ACE
inhibitors alone. Additional support for this possibility inhibitor [73]. This study indicates distinct roles for Ang
II and ET-1 in CsA-induced nephrotoxicity, such thatrests on recent findings we obtained in an accelerated
model of passive Heymann nephritis. Disease progres- ET-1 mediates the vasoconstriction, while Ang II medi-
ates fibrosis. We have shown that a mixed ET antagonistsion in this model is only partially modulated by ACE
inhibitors, which only modestly limit proteinuria in this prevented the acute vasoconstriction and reduction of
renal function induced by high-dose CsA [72].circumstance. Yet combining the two approaches did
significantly ameliorate renal function and renal injury, Dr. Campbell Wilson (Zeneca Pharmaceuticals, Mac-
clesfield, England, UK): Your overall message was thatthat is, glomerulosclerosis and tubulointerstitial damage,
more than did each drug alone [111]. we have to do clinical studies with ET receptor antago-
nists because the compounds are available for humanDr. Madias: Obstructive uropathy is a condition of
markedly increased renal Ang II and TGF-b. Is ET-1 use. Do you think we have sufficient experimental data
to start studies in humans?also upregulated in this situation?
Dr. Benigni: Few data in the model of obstructive Dr. Benigni: We have a lot of evidence of a renopro-
tective effect of ET receptor antagonists in progressiveuropathy show increased renal synthesis and urinary ex-
cretion of the peptide either in the rat or in the pig. renal diseases. The 5/6 nephrectomy model—especially
if created with the uninephrectomy and ligation of twoReyes and Klahr used specific anti-ET-1 antibody to
describe the contribution of ET-1 to the changes in renal branches of the renal artery of the contralateral kidney—
benefits quite dramatically from either ETA or mixedfunction observed after ureteral obstruction [112]. None
of these studies employed ET receptor antagonists. antagonists [52–54]. The same goes for accelerated pas-
sive Heymann nephritis, an immune-mediated model ofDr. Madias: Regarding the cyclical decrease in renal
hemodynamics and increases in urinary ET-1 excretion progressive renal disease accelerated by right nephrec-
tomy, which mimics the condition of patients in whomassociated with oral cyclosporine A (Sandimmune) ad-
ministration, have you made similar observations with ACE inhibitors are not completely effective. In this
model, the combination of an ACE inhibitor with an ETother CsA preparations? Does maintenance of a rela-
tively stable CsA level via intravenous infusion prevent receptor antagonist rather than each drug alone con-
ferred maximal renoprotection [111]. There are otherthese changes?
Dr. Benigni: We studied Sandimmune because other reports of beneficial effects of ET receptor antagonists
in experimental diabetes [56, 57], lupus nephritis [55],CsA preparations were not available at that time. Within
four hours after the peak blood concentration was aminonucleoside nephrosis [113], immune-complex ne-
phritis induced by repeated injections of ovalbuminreached, patients showed a transient renal hypoperfusion
associated with increased urinary ET-1 excretion. As [114], and chronic transplant rejection [83]. I do believe
that the experience accumulated so far in animal modelsblood levels of CsA returned to trough, renal function
progressively returned to baseline, as did urinary ET-1 is more than enough; we don’t need more to perform
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clinical trials. The problems of extending animal experi- An estimated 40% of patients with chronic progressive
ence to humans will remain because of the difference nephropathies do not fully respond to ACE inhibition
between species in ET receptor distribution. Which renal alone or do not respond at all. For this group of patients,
disease should be approached first in patients also is an we should consider adding drugs that target mediators
issue here. like MCP-1, TGF-b, and endothelin.
Dr. Brooks: The reluctance to begin clinical studies Dr. Madias: What do you think are the necessary
in patients with progressive renal disease mainly rests steps before we can perform these studies? Do we need
on the long-term nature of such studies. An additional more pre-clinical work, or in your judgment are we ready
problem can be that animal results are not always consis- to embark on a study?
tent and persuasive. A number of investigators showed Dr. Remuzzi: I disagree with Drs. Bender and Brooks.
a negligible effect of ET antagonists in some models, Because a lot of pre-clinical evidence consistently shows
and there are inconsistencies in the results in comparable that in every model endothelin antagonists have some
conditions. For instance, in experiments in the remnant beneficial effects, I don’t think we should embark on a
kidney model as well as in models of spontaneous hyper- long-term clinical study. We need short pilot studies in
tension, we have obtained less-than-convincing data. patients who do not respond or only respond partially to
Dr. Benigni: The compound you are dealing with is
an ACE inhibitor. It is more important now to determine
critical. This is also true for classes of compounds other
which drug combination will add an antiproteinuric ef-than the ACE inhibitors. One compound can be more
fect to that achieved by ACE inhibition in patients whorenoprotective than another, so identifying the best com-
are poor responders or non-responders.pound at the outset is critical before it is used in the
Dr. Madias: Do you think, then, that we are ready toclinic. Another aspect is, what are you going to measure
embark on a study in non-responders to ACE inhibitors?to establish the effectiveness of these compounds? Nor-
Dr. Remuzzi: Yes, and we also should consider pa-mally they do not lower blood pressure or reduce pro-
tients in whom ACE inhibitors reduce proteinuria onlyteinuria. The lack of this latter effect is consistent with
by 20% to 30%. The goal is to lower the urinary proteinthe possibility that excessive renal ET-1 synthesis is likely
level to less than 1 g. This is achievable with high enoughthe consequence rather than the cause of proteinuria.
doses and long enough treatment, as Dr. Fogo’s groupBy contrast, ET receptor antagonists have to be evalu-
and we already have shown in animals and humans [115,ated for their ability to limit renal functional deteriora-
116]. If proteinuria falls to lower than 1 g/day, nephropa-tion and damage and consequently to prolong survival.
Dr. Loeffler: On the applicability of animal data to thy does not progress. Using ACE inhibitors as the foun-
humans, I am concerned about the use of the rat model dation of therapy, you can use a multiple drug treatment;
to mimic human renal disease. Particularly regarding the certainly ET antagonists are good candidates for such a
remnant kidney model, results cannot be extrapolated regimen. With such an approach, a one-month study in
to other animals except rats. I think we need a model a reasonable number of selected patients might provide
different from the rat with receptor distribution and func- an important insight into the direction to pursue and
tion much more similar to those in humans. preclude the need for long-term studies.
Dr. Remuzzi: It might be true that rat models, particu- Dr. Loeffler: Chronic renal failure and congestive
larly the remnant kidney one, are in some sense artificial heart failure are governed by multiple factors that histor-
and do not reflect what happens in patients with progres- ically have puzzled physicians regarding the best choice
sive nephropathies. However, results of clinical trials in of therapy. We now have enough basic data to show a
renal disease progression have been predicted accurately fine network of “crosstalk” between different systems,
by remnant kidney studies in rats. After so many years
the RAS system and the ET system, that are activated
of research on proteinuria and progressive diseases, one
in these diseases. Based on this information, therapiescan conclude that a drug capable of effectively reducing
interfering with only Ang II formation or ET-1 receptorsproteinuria in animals has a good chance of being salu-
will probably only be partially effective. Blocking thetary in humans if patients are treated long enough.
crosstalk between the systems with a combination ofThe introduction of ACE inhibitors has been a major
drugs might give us more insight into what treatmentadvance in the treatment of chronic progressive ne-
plan is superior.phropathy. However, the more we study progressive ne-
Dr. Bender: I fully agree with Drs. Loeffler and Re-phropathy, the clearer it is that in some patients, ACE
muzzi. Today the term “pharmacogenomics” is very pop-inhibitors cannot lower proteinuria to any significant ex-
ular and is basically the beginning of the whole story.tent. When proteinuria is not reduced despite ACE inhi-
The future is the multidrug treatment that will allow usbition, the renal disease tends to progress. These are the
to identify genetically what type of drugs we will needpatients in whom more than one drug probably is needed
to effectively lower protein traffic and induce remission. to use in which patients.
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